ReviewMedical oncology (Northwood, London, England)2025
3D bioprinting innovations: a new frontier in breast cancer research.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Technological Innovation to Clinical Translation: Progress and Challenges in 3D Bioprinting for the Development of Breast Cancer Bone Metastasis Models.Advanced healthcare materials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Breast cancer (BC) is a widely recognized second most frequent female cancer globally that is histologically and molecularly heterogeneous. Nevertheless, despite intensive studies, currently available preclinical models, particularly animal models, are of limited use for clinical applications, and thus, anticancer drug failure in clinical trials is relatively high. This gap indicates the necessity for more physiologically relevant models. Conventional two-dimensional (2D) culture models are incapable of accurately simulating the complex tumor microenvironment. However, three-dimensional (3D) cell culture and bioprinting technologies offer better options by more accurately resembling the tissue structure of original tissues and cellular activities. 3D bioprinting is capable of precise deposition of living cells and extracellular matrix (ECM) components into a predefined structure, which subsequently enables the generation of breast cancer tissue (BCT) models that closely simulate in vivo conditions. This review examines the limitations of current models, explores the potential of 3D bioprinting in developing functional and dynamic BC models, and evaluates bioinks, printing strategies, and metastatic models. We conclude by addressing the existing challenges and future directions for advancing 3D bioprinting applications.
Indexed as
Identifiers
41249752What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.